Skip to main content
2022 Guide to Patient Support Services


2022 Oncology Guide to Patient Support Services

Eisai Reimbursement Resources


Eisai offers drug-specific reimbursement assistance to patients taking Halaven or Lenvima (Table).

Eisai Reimbursement Resources

Eisai Reimbursement Resources offers a $0 Co-Pay Program, a Patient Assistance Program, and the Lenvima Dose Exchange Program.

$0 Co-Pay Program

The $0 Co-Pay Program provides assistance for patients with commercial insurance who have been prescribed Halaven or Lenvima for an approved indication. The program is not available to patients enrolled in state or federal healthcare programs, including Medicare, Medicaid, Medigap, Veterans Administration, Department of Defense, or TRICARE.

Patient Assistance Program

Halaven and Lenvima may be available at low cost or no cost to financially needy patients who meet the program’s eligibility criteria, including US residency, income status, and site-of-service specifications. Coverage and payment depend on the patient’s insurance plan.

Lenvima Dose Exchange Program

Eligible patients who require a dose reduction can exchange up to 15 unused doses for the same number of doses at the reduced dose strength at no additional cost.

TABLE Eisai Oncology Drugs

Patient support programs

Halaven (eribulin mesylate)
Treatment of metastatic breast cancer previously treated with at least 2 chemotherapeutic regimens. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting; unresectable or metastatic liposarcoma previously treated with an anthracycline-containing regimen
Patient support programs

Lenvima (lenvatinib) Indications

Treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer; in combination with pembrolizumab as first-line treatment of adult patients with advanced renal-cell carcinoma (RCC); in combination with everolimus in advanced RCC following 1 prior anti-angiogenic therapy; as first-line treatment of unresectable hepatocellular carcinoma; in combination with pembrolizumab, for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability-high or mismatch repair deficient, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation

Report Broken Links

Have you encountered a problem with a URL (link) on this page not loading correctly or is displaying an error message?

Help us fix it! Report broken links here.

Report Broken Links

Report Broken Links

*OPM Webpage
Please copy the URL (link) of the OPM webpage you are currently on.
*Broken Link
Please copy the URL (link) to the external webpage that is not displaying content correctly.
Errors include, but are not limited to:
  • "This site can’t be reached"
  • "Hmm. We’re having trouble finding that site."
  • "Hmmm… can't reach this page"
  • "404 Error: Page not found"